Why the study?
Does a polymer-free rapamycin- and probucol-eluting stent reduce binary angiographic restenosis compared to permanent polymer-based sirolimus- or zotarolimus-eluting stents in patients undergoing coronary stenting of de novo lesions?
Does a polymer-free rapamycin- and probucol-eluting stent reduce binary angiographic restenosis compared to permanent polymer-based sirolimus- or zotarolimus-eluting stents in patients undergoing coronary stenting of de novo lesions?
A novel polymer-free rapamycin- and probucol-eluting stent demonstrated superior anti-restenotic efficacy compared to zotarolimus-eluting stents and comparable efficacy to sirolimus-eluting stents.
No takes yet. Share an insight, caveat, or question.
Polymer-free Dual-DES may be favored over ZES for de novo lesions; extends RCT evidence on polymer-free versus permanent-polymer platforms.
Byrne et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: